台湾地区乳腺癌患者血清 HER2 ECD、TIMP-1 与临床结局的关系。
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
机构信息
Graduate Institute of Clinical Medical Sciences,Chang Gung University, Tao-Yuan, Taiwan.
出版信息
World J Surg Oncol. 2012 Feb 17;10:42. doi: 10.1186/1477-7819-10-42.
BACKGROUND
Serum levels of the extracellular domain of HER2/neu (HER2 ECD) have been demonstrated to be associated with clinical outcomes. A disintegrin and metalloproteinase-10, a sheddase of HER2/neu, can drive cancer progression and its activity is inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1). However, elevated TIMP-1 expression has been associated with a poor prognosis of breast cancer. Therefore, this study was performed to explore the relationships between serum HER2 ECD, TIMP-1 and clinical outcomes.
METHODS
One hundred and eighty-five female breast cancer patients, who received curative mastectomy without neo-adjuvant chemotherapy at Chang-Gung Memorial Hospital, were recruited with informed consent for this study. Pre-operative serum levels of HER2 ECD and TIMP-1 were measured using an enzyme-linked immunosorbent assay.
RESULTS
Twenty-three cases (12.4%) were classified HER2 ECD positive. HER2 ECD positivity was significantly associated with age, lymph node involvement, histological grade, estrogen receptor status, progesterone receptor status, tissue HER2/neu overexpression, and disease-free survival (DFS). In an age, stage, ER and HER2/neu status matched subgroup (N = 41), the serum level of TIMP-1 was significantly associated with HER2 ECD positivity and DFS.
CONCLUSIONS
A high serum TIMP-1 was significantly associated with HER2 ECD positivity and a poorer DFS among Taiwanese primary breast cancer patients with HER2 overexpression.
背景
已经证明，HER2/neu（HER2 ECD）的细胞外结构域的血清水平与临床结果相关。解整合素金属蛋白酶 10（一种 HER2/neu 的脱落酶）可驱动癌症进展，其活性受金属蛋白酶组织抑制剂-1（TIMP-1）抑制。然而，TIMP-1 表达升高与乳腺癌预后不良相关。因此，进行这项研究是为了探讨血清 HER2 ECD、TIMP-1 与临床结果之间的关系。
方法
本研究共纳入 185 名在长庚纪念医院接受根治性乳房切除术且未接受新辅助化疗的女性乳腺癌患者。本研究获得了每位患者的知情同意。使用酶联免疫吸附测定法测量术前血清 HER2 ECD 和 TIMP-1 水平。
结果
23 例（12.4%）被归类为 HER2 ECD 阳性。HER2 ECD 阳性与年龄、淋巴结受累、组织学分级、雌激素受体状态、孕激素受体状态、组织 HER2/neu 过表达和无病生存期（DFS）显著相关。在年龄、分期、ER 和 HER2/neu 状态匹配的亚组（N=41）中，TIMP-1 血清水平与 HER2 ECD 阳性和 DFS 显著相关。
结论
在台湾具有 HER2 过表达的原发性乳腺癌患者中，高血清 TIMP-1 与 HER2 ECD 阳性和较差的 DFS 显著相关。
Zotero 插件